Gastrointestinal Tolerance of Dietary Fiber
Conditions
Keywords
Fiber Tolerance Gastro-intestinal Safety
Brief summary
Research shows that many people do not get enough dietary fiber through their normal diet. As a result, some nutrients are not properly absorbed into the bloodstream. The immune system however does need these nutrients. Dietary fibers are therefore important for health. Nutricia has developed a new blend of natural fibers that can help people get enough fiber.
Interventions
DIETARY_SUPPLEMENTFiber
Subjects in this study are to consume the study product twice daily during regular meals. The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption.
Sponsors
NCRU (Nutrition Clinical Research Unit)
Nutricia Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
open-label, single-arm, single-site
Eligibility
Sex/Gender
ALL
Age
45 Years to 69 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age ≥ 45 and ≤ 70 years 2. Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 3. Signed consent form 4. Willingness and ability to comply with the protocol 5. Good general health 6. Defecation frequency: between three bowel movements per week and three bowel movements per day within a month for screening.
Exclusion criteria
1. Presence or history of chronic gastrointestinal disorders (e.g. stomach ulcers, ulcerative colitis, Crohn's disease) or history of abdominal surgery with resection of the bowel (small or large intestine). 2. Presence of other medical conditions where gastrointestinal function often/probably is affected, such as: 1. autoimmune diseases (e.g. diabetes mellitus type I, multiple sclerosis, systemic lupus erythematosus). 2. eating disorders (e.g. anorexia nervosa, bulimia nervosa, binge eating disorder). 3. intestinal/gastrointestinal disorder due to a stroke. 3. Chronic diseases (including but not limited to hypertension, dyslipidaemia, type 2 diabetes mellitus, thyroid disorders) that cannot be controlled with the use of medication/therapy. 4. Severe acute liver disease or chronic liver disease. 5. Severe or chronic kidney disease or need for hemodialysis. 6. Colonoscopy, irrigoscopy or other bowel cleansing, or other surgical procedures related to the gastrointestinal tract (eg. colon polypectomy, appendectomy) or for which use of systemic antibiotics within 1 month before the screening is required or scheduled during participation in the study. 7. Use of enemas, laxatives, antacids, proton pump inhibitors, prokinetics (e.g. metoclopramide, drugs that affect motility), digestive enzymes, narcotic/morphine analgesics within 1 week prior to screening or intended use during participation in the study. 8. Following a vegetarian or vegan diet.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GSRS change | 4 weeks | Change from baseline in the reported severity of GI symptoms assessed by the Gastrointestinal Symptom Rating Scale (GSRS) for diarrhea dimension at week 4 post-baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GSRS change | week 1, week 2, week 3, | Weekly changes from baseline in the reported severity of GI symptoms assessed by the GSRS for diarrhea dimension at week 1, week 2, and week 3 post-baseline. |
Other
| Measure | Time frame | Description |
|---|---|---|
| BSFC | week 1, week 4 | Weekly average faecal form type assessed by the Bristol Stool Form Chart at each defecation in the baseline week, at week 1, and week 4 post-baseline. |
| DQLQ | 4 weeks | Digestion-associated Quality of life assessed by the Digestion-associated Quality of Life Questionnaire (DQLQ) at baseline and at week 4 post-baseline. |
| Stool | week 2, week 3, week 4 | Microbiota and other outcome parameters assessed using collected faecal samples in the baseline week and every 7 days over 4 weeks post-baseline: * Composition, diversity, and abundance of microbiota using 16S rRNA gene sequencing and processing * Short-chain fatty acids (SCFA) * Branch-chain fatty acids (BCFA) * Lactate * Ammonia * Calprotectin * Secretory immunoglobulin A (sIgA) * pH |
| Defecation frequency | week 1, week 2, week 3, week 4 | Weekly average frequency of defecation, derived from the number of faecal form types assessed by the Bristol Stool Form Chart. |
| GSRS | week 1, week 2, week 3, week 4 | The reported severity of GI symptoms assessed by the GSRS between week 1 v week 2, week 1 v week 3, week 1 v week 4, week 2 v week 3, week 2 v week 4, and week 3 v week 4 \[score\]. |
Countries
Netherlands
Outcome results
None listed